Hemostasis Today

April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Ramy Abdelnaby: The Impact of Multiterritory Brain Infarcts on Recurrent Stroke Risk and Anticoagulation Efficacy
Mar 9, 2026, 14:05

Ramy Abdelnaby: The Impact of Multiterritory Brain Infarcts on Recurrent Stroke Risk and Anticoagulation Efficacy

Ramy Abdelnaby, Consultant Neurologist / Oberarzt at RWTH Aachen University Hospital, shared on LinkedIn about a recent article by Rachel Gologorsky et al, published in Stroke Journal:

”A pivotal subgroup analysis of the ARCADIA trial, recently published in Stroke, illuminates the impact of multiterritory brain infarcts on recurrent stroke risk and the efficacy of anticoagulation in cryptogenic stroke patients.

The comprehensive study spanned from 2018 to 2022 across 185 centers, exploring atrial cardiopathy’s role in stroke recurrence and anticoagulation response.

Key findings reveal no significant association between atrial cardiopathy biomarkers, LVEF, and the number of infarct territories.

Yet, it’s the detailed examination of recurrent stroke risk and anticoagulation effects that promises to redefine clinical strategies.”

Title: Multiterritory Brain Infarcts, Anticoagulation, and Recurrence After Cryptogenic Stroke: A Subgroup Analysis of the ARCADIA Trial

Authors: Rachel Gologorsky, Maarten G. Lansberg, Max Wintermark, Christy N. Cassarly, Rebeca Aragon Garcia, Pamela Plummer, Nilushi Karunamuni, Scott E. Kasner, Babak B. Navi, Ava Liberman, Mukul Sharma, Joseph P. Broderick, W.T. Longstreth Jr., David L. Tirschwell, Richard A. Kronmal, Mitchell S.V. Elkind, Hooman Kamel

Read the Full Article on Stroke

Ramy Abdelnaby: The Impact of Multiterritory Brain Infarcts on Recurrent Stroke Risk and Anticoagulation Efficacy

Stay updated on all scientific advances with Hemostasis Today.